Tryptamine Therapeutics Limited Stock

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin), which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.